Navigation Links
Stem Cells Might Beat Drugs in Delivering Relief Faster, More Effectively to Rheumatoid Arthritis Sufferers
Date:4/16/2013

Durham, NC (PRWEB) April 16, 2013

Can stem cell therapy outperform a drug commonly considered the gold standard for treating rheumatoid arthritis? A new study in rodents published in the current issue of STEM CELLS Translational Medicine indicates perhaps so.

The findings could lead to a faster, safer, more effective way to bring relief to the up to 70 million people estimated to suffer from this disease worldwide.

Rheumatoid arthritis (RA) is a chronic condition that causes pain, stiffness, swelling and limited motion and function of many joints. While it can affect any joint, RA tends to settle mainly in a patient’s hands and feet. The results can be debilitating.

People who have RA overproduce a protein called tumor necrosis factor (TNF), which causes the inflammation and damage to the bones, cartilage and tissue. Anti-TNF drugs can block the action of the protein and reduce inflammation. Etanercept® (marketed under the trade name Enbrel) is a type of anti-TNF drug called a biologic that for years has been prescribed to treat RA. However, it can’t be targeted specifically to the site of the arthritis and, thus, requires higher doses that can cause serious side effects including fatal infections, multiple sclerosis, seizures, heart failure, cancer and more.

“Moreover, biologics in general require intense development and manufacturing processes that are challenging for reproducibility, even within the same company. So we wanted to see how delivering treatment through a very targeted system such as that which can be done using stem cells compared to a biologic drug such as Etanercept®,” said Joseph Mosca, Ph.D. He led the team of researchers from Osiris Therapeutics, Inc. Baltimore, Md., and the Novartis Research, Basel, Switzerland, in conducting the study.

The researchers began by genetically altering human mesenchymal stem cells (MSCs) in the lab to become vehicles for the cell-based anti-TNF delivery. They then injected the cells into mice that had been induced with RA and monitored them over a seven-day period, then compared the results to a group of animals treated with Etanercept®. The results showed that the anti-TNF therapy delivered by stem cells reversed or attenuated the arthritis inflammation on par with the Etanercept® — except that it did it faster.

“If this translates into fewer side-effects and/or lower compliance remains to be seen,” Dr. Mosca said. “In either case, these results illustrate the ability of stem cells to deliver proteins of therapeutic value and demonstrate their potential clinical utility in rheumatoid/osteoarthritis and other TNF-related diseases where anti-TNF biologic drugs have already shown promise.”

“The authors have shown the feasibility of a targeted approach to treatment using cells that are known to ‘home’ to damaged tissue,” said Anthony Atala, M.D., Editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. “The manuscript supports and demonstrates the potential of mesenchymal stem cells as a vehicle for cell-based gene delivery.”

###
The full article, “Comparison of Drug and Cell-Based Delivery—Engineered Adult Mesenchymal Stem Cells Expressing Soluble Tumor Necrosis Factor Receptor-II Prevent Arthritis in Mouse and Rat Animal Models,” can be accessed at http://www.stemcellstm.com.

About STEM CELLS Translational Medicine: STEM CELLS TRANSLATIONAL MEDICINE (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (http://www.StemCells.com), in its 31st year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 18th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10635431.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Preliminary Research, Led By Dr. Vincent Giampapa, Finds Aged Adult Stem Cells Can Be Functionally Reprogrammed To Act Like Younger Cells
2. New Method for Mass-Producing RPE Cells Paves Way to Treating Age-Related Blindness
3. Sigma Life Science and the Culture Collections of Public Health England Collaborate to Distribute Cells and Cellular Extracts
4. New Way to Mass-produce Natural Cancer-killing Cells Offers Hope for Patients
5. Tenfold boost in ability to pinpoint proteins in cancer cells
6. Stem cells produce compact, regenerated bone in mandible transplants
7. Transplanted brain cells in monkeys light up personalized therapy
8. U of T engineering breakthrough promises significantly more efficient solar cells
9. Dr. Carlos Szajnert, Announced today his Commitment to Further Educate his Patients on the Benefits of Cord Blood Stem Cells
10. UCLA researchers further refine NanoVelcro device to grab single cancer cells from blood
11. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Francisco, CA (PRWEB) , ... February 20, 2017 ... ... Inc. announced today the re-launch of “Crosswalk Insight: Oncology™” (Crosswalk), a unique precision ... version of Crosswalk can now be accessed through Inspirata’s diagnostic cockpit and is ...
(Date:2/20/2017)... , ... February 20, 2017 ... ... therapeutic success among radiotherapy patients, prevent chest wall collapses in pre-term infants ... alignments will receive a total of $600,000 in funding through the ninth ...
(Date:2/20/2017)...  Former NFL players who had repeated head injuries may ... according to a preliminary study released today that will be ... in Boston , April 22 to 28, ... the muscles and nerves work together, like walking, kicking and ... ...
(Date:2/20/2017)... , Feb. 20, 2017  Atrius Health and ... entered into an agreement to develop a cloud ... By providing a holistic view of the multiple ... Watson Cognitive Insights could be designed to support ... Health is an innovative nonprofit healthcare organization with ...
Breaking Biology Technology:
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/25/2017)... 2017 The Elements of Enterprise Information Security ... comprised of a comprehensive set of business processes ... digital identities and providing a secured and documented ... significant number of programs opted by enterprises to ... optimizing processes and changing policies. However, there are ...
Breaking Biology News(10 mins):